Healthcare Team

Bryan, Garnier & Co Healthcare Daily | TNG, Initiations: ACHL, AUTL, CLLS, CRSP

Achilles Corp.

Achilles is mainly engaged in the manufacture and sale of shoes, plastic products and industrial materials. Along with its subsidiaries and associated companies, Co.'s principal business segments are shoes, plastic products, and industrial material. Co.'s principal products are shoes such as "ACHILLES SORBO," "SYUNSOKU LemonPie, " "SYUNSOKU DANCE," "SYUNSOKU BABY," and "SPALDING"; synthetic leather "Super Carbon" for car seats, paste leather "Partner" for car seats, and paste leather for car door molds; and ranging from interior materials that enhance the look of the home to insulating materials and rigid fluorocarbon-free urethane foam insulating materials.

Autolus Therapeutics ADS

Cellectis SA

Cellectis is a gene-editing company employing its core proprietary technologies to develop products in the field of immuno-oncology. UCART19 is Co.'s lead product. UCART19 is an engineered T-cell product which drives its ability to target and kill CD19-bearing cells, such as B-cell malignancies. Co. is also developing wholly-owned product candidates UCART123, UCARTCS1 and UCART38, which are in various stages of development. UCART 123, UCARTCS1 and UCART38 are engineered T-cell products that bear CARs that seek to kill cells expressing targets CD123, CS1 and CD38, respectively, which are found in other hematologic tumors, such as acute myeloid leukemia, or AML, and multiple myeloma, or MM.

CRISPR Therapeutics AG

Transgene Biotek

Transgene Biotek is a biotechnology company based in India. Co. is engaged in the development of therapeutic and preventative pharmaceuticals. Co. maintains a product portfolio which includes therapeutic areas such as Bio-generics, Oncology and New Drug Delivery Systems among others. Co.'s products are categorized under 4 main technology platforms: Bio-Generic Drugs, which includes Orlistat, Tacrolimus and recombinant Erythropoietin; Novel Drug Delivery Technology for the oral delivery of protein drugs, with the first two targets being Insulin and Hep B vaccine; platforms for drugs against auto-immune diseases; and Oncology drugs encompassing RNAi technology as well as monoclonal antibodies.

Bryan Garnier
Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

Healthcare Team

ResearchPool Subscriptions

Get the most out of your insights

Get in touch